← Leaderboards
Kumar Sharma
South Texas Veterans Health Care System
$19,256,494
Attributed
$29,251,358
Total exposure
15
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,251,358 · 11
VA$0 · 4
By mechanism
R24$7,271,245 · 1
DP3$5,950,661 · 1
U01$4,944,962 · 2
R01$4,045,156 · 2
R44$2,998,612 · 1
UH3$2,741,510 · 1
Top collaborators
- Frank C Brosius6 shared
- Eva L Feldman6 shared
- Matthias Kretzler6 shared
- Subramaniam Pennathur6 shared
- Theodore Alexandrov4 shared
- Christopher R Anderton4 shared
- Thomas W. Gardner4 shared
- H V Jagadish4 shared
Most similar at South Texas Veterans Health Care System
Same institution · by research overlap
- Goutam Ghosh Choudhury$3,326,680
Others in their field
Top investigators on “Kidney”
- Jeffrey P Krischer · University Of South Florida$540,222,210
- John M Lachin · George Washington University$155,894,464
- David M Nathan · Massachusetts Institute Of Technology$127,229,266
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$111,521,899
- David Heimbrook · Leidos Biomedical Research, Inc.$83,221,586
- Peter Scott Heeger · Case Western Reserve University$80,562,246
Research focus
KidneyPathway InteractionsDiabetic NephropathyKidney DiseasesBaseDiabetes MellitusTissuesIn VivoDiabeticMetabolomicsBiological MarkersCellsMorbidity - Disease RateChronic Kidney FailurePlayProteinsFundingPathogenesisMolecularDisease ProgressionMetabolismLinkMortalityLead
Grant awards (59)
Spatial Multi-Omics to Profile Metabolic Pathways for Kidney Disease$823,813
U01 · FY2025 · DK · contact PI
New Insights in Mechanisms of Renal Injury$0
I01 · FY2025 · VA · contact PI
Spatial Multi-Omics to Profile Metabolic Pathways for Kidney Disease$790,861
U01 · FY2024 · DK · contact PI
Mechanisms of Renal Cell Injury$0
I01 · FY2024 · VA · contact PI
New Insights in Mechanisms of Renal Injury$0
I01 · FY2024 · VA · contact PI
Spatial Multi-Omics to Profile Metabolic Pathways for Kidney Disease$823,814
U01 · FY2023 · DK · contact PI
New Insights in Mechanisms of Renal Injury$0
I01 · FY2023 · VA · contact PI
Spatial Multi-Omics to Profile Metabolic Pathways for Kidney Disease$823,826
U01 · FY2022 · DK · contact PI
Precision Mass Spec Imaging Based Structure-Function Signatures of Diabetic Glomerulopathy$6,500
R43 · FY2022 · DK
Spatial Metabolomics for Human Kidneys$993,136
UH3 · FY2021 · DK · contact PI
Precision Mass Spec Imaging Based Structure-Function Signatures of Diabetic Glomerulopathy$300,000
R43 · FY2021 · DK
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,364,409
R24 · FY2020 · DK
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis$999,838
R44 · FY2020 · DK
Spatial Metabolomics for Human Kidneys$529,835
UH3 · FY2020 · DK · contact PI
Nicotinamide Riboside for AKI in COVID-19 positive inpatients$502,216
UH3 · FY2020 · DK · contact PI
Spatial Metabolomics for Human Kidneys$186,487
UH3 · FY2020 · DK · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,368,284
R24 · FY2019 · DK
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis$999,274
R44 · FY2019 · DK
Spatial Metabolomics for Human Kidneys$429,836
UH3 · FY2019 · DK · contact PI
Spatial Metabolomics for Human Kidneys$100,000
UH3 · FY2019 · DK · contact PI
New Insights in Mechanisms of Renal Injury$0
I01 · FY2019 · VA · contact PI
Mitochondrial-Derived Superoxide in Type 2 Diabetic Kidney Disease$0
I01 · FY2019 · VA · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,374,854
R24 · FY2018 · DK
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis$999,500
R44 · FY2018 · DK
Spatial Metabolomics for Human Kidneys$429,836
UG3 · FY2018 · DK · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$390,000
R24 · FY2018 · DK
New Insights in Mechanisms of Renal Injury$0
I01 · FY2018 · VA · contact PI
Mitochondrial-Derived Superoxide in Type 2 Diabetic Kidney Disease$0
I01 · FY2018 · VA · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,378,119
R24 · FY2017 · DK
Spatial Metabolomics for Human Kidneys$438,811
UG3 · FY2017 · DK · contact PI
Mitochondrial-Derived Superoxide in Type 2 Diabetic Kidney Disease$0
I01 · FY2017 · VA · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,395,579
R24 · FY2016 · DK
Mitochondrial-Derived Superoxide in Type 2 Diabetic Kidney Disease$0
I01 · FY2016 · VA · contact PI
Adiponectin and Podocytes$0
I01 · FY2013 · VA · contact PI
Adiponectin and Podocytes$0
I01 · FY2012 · VA · contact PI
Novel Paradigms in Diabetic Complications$5,950,661
DP3 · FY2011 · DK · contact PI
Adiponectin and Podocytes$0
I01 · FY2011 · VA · contact PI
Adiponectin and Nox 4 in Diabetic Kidney Disease$347,441
U01 · FY2010 · DK · contact PI
Adiponectin and Nox 4 in Diabetic Kidney Disease$319,823
U01 · FY2009 · DK · contact PI
TGF-b signaling in diabetic kidney disease$315,841
R01 · FY2009 · DK · contact PI
Adiponectin and Nox 4 in Diabetic Kidney Disease$96,400
U01 · FY2009 · DK · contact PI
Adiponectin and Podocytes$0
I01 · FY2009 · VA · contact PI
Adiponectin and Nox 4 in Diabetic Kidney Disease$319,824
U01 · FY2008 · DK · contact PI
TGF-b signaling in diabetic kidney disease$315,841
R01 · FY2008 · DK · contact PI
Adiponectin and Nox 4 in Diabetic Kidney Disease$308,535
U01 · FY2007 · DK · contact PI
TGF-b signaling in diabetic kidney disease$231,511
R01 · FY2007 · DK · contact PI
TGF-b signaling in diabetic kidney disease$84,935
R01 · FY2007 · DK · contact PI
TGF-b signaling in diabetic kidney disease$332,590
R01 · FY2006 · DK · contact PI
Adiponectin and Nox 4 in Diabetic Kidney Disease$290,625
U01 · FY2006 · DK · contact PI
TGF-b signaling in diabetic kidney disease$343,200
R01 · FY2005 · DK
Pirfenidone: Anti-Scarring Drug for Diabetic Nephropathy$281,942
R01 · FY2005 · DK
Pirfenidone: Anti-Scarring Drug for Diabetic Nephropathy$58,058
R01 · FY2005 · DK
Pirfenidone: Anti-Scarring Drug for Diabetic Nephropathy$390,000
R01 · FY2004 · DK
Pirfenidone: Anti-Scarring Drug for Diabetic Nephropathy$392,500
R01 · FY2003 · DK
Pirfenidone: Anti-Scarring Drug for Diabetic Nephropathy$392,500
R01 · FY2002 · DK
PKA AND IP3R BY TGFB IN DIABETIC KIDNEY DISEASE$330,338
R01 · FY2002 · DK
PKA AND IP3R BY TGFB IN DIABETIC KIDNEY DISEASE$323,629
R01 · FY2001 · DK
PKA AND IP3R BY TGFB IN DIABETIC KIDNEY DISEASE$252,271
R01 · FY2000 · DK
REGULATION AND ACTION OF TGFB IN DIABETIC KIDNEY DISEASE$124,065
K08 · FY2000 · DK